Cargando…
Screening for prostate cancer: a study on the free and total prostate specific antigen
Background: A variety of biomarkers have been developed to monitor growth of cancerous diseases and to detect them at an early stage. Prostate-specific antigen (PSA) is a valuable prostate cancer biomarker that is now widely used for population screening, diagnosis, and monitoring of patients with p...
Autores principales: | Mediu, Ridvana, Rama, Ariol, Mediu, Naim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Applied Systems srl
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960002/ https://www.ncbi.nlm.nih.gov/pubmed/35359347 http://dx.doi.org/10.15190/d.2021.18 |
Ejemplares similares
-
Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
por: Wald, N J, et al.
Publicado: (2000) -
Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate
por: Agnihotri, Shalini, et al.
Publicado: (2014) -
Free Prostate-Specific Antigen Provides More Precise Data on Benign Prostate Volume Than Total Prostate-Specific Antigen in Korean Population
por: Choi, Hoon, et al.
Publicado: (2013) -
Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015) -
Bioimpedance and chronoamperometry as an adjunct to prostate-specific antigen screening for prostate cancer
por: de Abreu, Darci Schiavon
Publicado: (2011)